Indeed, in our material, PMA, an activator of protein kinase C (PKC) that triggers NETs release in a reactive oxygen species (ROS)-dependent manner [5,32], was unable to induce NETs formation in neutrophils isolated from ALL and AML patients before the initiation of antileukemic treatment (Figure 1) and in most of the patients after the first induction therapy (Figure 3A). The gene discussed is PRRT2; the disease is acute myeloid leukemia.